# Patterns of physical activity progression in patients with COPD

STROBE Statement—Checklist of items that should be included in reports of ***cohort studies***

| | Item No | Recommendation | Page No |
|---|---|---|---|
| **Title and abstract** | 1 | (*a*) Indicate the study's design with a commonly used term in the title or the abstract | 2 (abstract page) of main text |
| | | (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 (abstract page) of main text |
| **Introduction** | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 4 of main text |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 4-5 of main text |
| **Methods** | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5 of main text |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5 of main text |
| Participants | 6 | (*a*) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up | 5 of main text |
| | | (*b*) For matched studies, give matching criteria and number of exposed and unexposed | Not applicable |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 6-7 of main text |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 6-7 of main text |
| Bias | 9 | Describe any efforts to address potential sources of bias | 7-8 of main text, 2-3 of supplementary material |
| Study size | 10 | Explain how the study size was arrived at | 3 of supplementary material |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | 7-8 of main text, 2-3 of supplementary material |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | 7-8 of main text, 2-3 of supplementary material |
| | | (*b*) Describe any methods used to examine subgroups and interactions | 7-8 of main text, 2-3 of supplementary material |
| | | (*c*) Explain how missing data were addressed | 7, 22-23 (Table 1) and 24-25 (Table 2) of main text; 5-7 (Tables S1 and S2) of supplementary material |

| | | | |
|---|---|---|---|
| | | (*d*) If applicable, explain how loss to follow-up was addressed | 7 of main text; 2, 4 (Figure S1) of supplementary material |
| | | (*e*) Describe any sensitivity analyses | 8 of main text, 2-3 of supplementary material |
| **Results** | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 8 of main text; 4 (Figure S1) of supplementary material |
| | | (b) Give reasons for non-participation at each stage | 4 (Figure S1) of supplementary material |
| | | (c) Consider use of a flow diagram | 4 (Figure S1) of supplementary material |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 8-10 and 22-23 (Table 1) of main text |
| | | (b) Indicate number of participants with missing data for each variable of interest | 22-25 (Tables 1 and 2) of main text, 5-7 (Tables S1 and S2) of supplementary material |
| | | (c) Summarise follow-up time (eg, average and total amount) | 8-10 of main text (Figures 1 and 2), 24-25 of main text (Table 2), 7 (Table S2 of supplementary material) |
| Outcome data | 15* | Report numbers of outcome events or summary measures over time | 8-10 and 24-26 of main text, (Tables 2 and 3) |

| | | | |
|---|---|---|---|
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | 8-10 and 24-26 of main text (Tables 2 and 3) |
| | | (*b*) Report category boundaries when continuous variables were categorized | 8-10 and 24-26 of main text (Tables 2 and 3) |
| | | (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | Not applicable |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | 9-10 of main text, 8-10 (Tables S3-S5) of supplementary material |
| **Discussion** | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 10 of main text |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 14 of main text |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 10-15 of main text |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | 13 of main text |
| **Other information** | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 6 of authorship page |